Mayo Clinic returned to reinvest in the genomics platform developer three years after backing its series B round alongside Illumina.
US-based genomics technology developer Helix has received $50m series C funding from investors including medical research group Mayo Clinic.
Venture capital firms DFJ Growth and Kleiner Perkins, Singaporean state-owned investment firm Temasek and private equity firm Warburg Pincus filled out the round.
Helix provides a personal genomics products and services platform which helps healthcare providers personalise patient treatments. The funding will be used to improve its offering, in areas including covid-19 testing and viral surveillance.
Mayo Clinic had taken part…
